Krause Kevin Michael — SEC Form 4 filings

SEC reporting owner CIK 1916925. 3 Form 4 filings on record with FilingPulse; latest filed 2024-03-29.

Transaction summary — filings shown

Covers all 3 filings on record, filed 2024-01-11 to 2024-03-29. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
AN2 Therapeutics, Inc. (ANTX)Chief Strategy Officer31 leg · 7,417 sh · $149,3677

Form 4 filings — Krause Kevin Michael

FiledFormIssuerReported transactionsSource
2024-03-294/AAN2 Therapeutics, Inc. (ANTX)Grant/award (A): 30,000 @ $0EDGAR
2024-03-184AN2 Therapeutics, Inc. (ANTX)Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0EDGAR
2024-01-114AN2 Therapeutics, Inc. (ANTX)Option exercise (M): 2,417 @ $0.42 · Option exercise (M): 5,000 @ $6.60 · Sale (S): 7,417 @ $20.14 · Option exercise (M): 2,417 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-10 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1916925 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →